LSV Asset Management Sells 218,077 Shares of Gilead Sciences, Inc. $GILD

LSV Asset Management cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.8% during the 3rd quarter, Holdings Channel.com reports. The fund owned 4,299,593 shares of the biopharmaceutical company’s stock after selling 218,077 shares during the period. Gilead Sciences accounts for about 1.1% of LSV Asset Management’s portfolio, making the stock its 12th biggest position. LSV Asset Management’s holdings in Gilead Sciences were worth $477,255,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. GoalVest Advisory LLC lifted its position in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. Corundum Trust Company INC purchased a new stake in Gilead Sciences in the 3rd quarter valued at about $26,000. Harbor Asset Planning Inc. purchased a new stake in Gilead Sciences in the 2nd quarter valued at about $27,000. Putney Financial Group LLC lifted its position in shares of Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 94 shares in the last quarter. Finally, Howard Hughes Medical Institute purchased a new position in shares of Gilead Sciences in the 2nd quarter worth approximately $30,000. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 115,640 shares of the business’s stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the sale, the chief executive officer directly owned 566,698 shares in the company, valued at approximately $76,504,230. The trade was a 16.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $125.86, for a total value of $3,524,080.00. Following the completion of the transaction, the insider owned 107,193 shares of the company’s stock, valued at approximately $13,491,310.98. This represents a 20.71% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 319,391 shares of company stock valued at $44,141,101 in the last ninety days. 0.27% of the stock is owned by company insiders.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $155.80 on Thursday. The firm has a market capitalization of $193.30 billion, a PE ratio of 23.01, a P/E/G ratio of 0.78 and a beta of 0.36. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The company has a 50-day moving average price of $129.01 and a two-hundred day moving average price of $121.77. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 51.04%. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.1%. Gilead Sciences’s dividend payout ratio is 46.68%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Royal Bank Of Canada increased their price target on Gilead Sciences from $103.00 to $118.00 and gave the company a “sector perform” rating in a research report on Wednesday. Wolfe Research raised their target price on Gilead Sciences from $150.00 to $155.00 and gave the company an “outperform” rating in a research report on Wednesday, January 28th. Scotiabank boosted their price target on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a report on Wednesday. HSBC increased their price target on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research report on Wednesday, December 10th. Finally, Morgan Stanley lifted their price objective on shares of Gilead Sciences from $150.00 to $171.00 and gave the stock an “overweight” rating in a research report on Wednesday. Twenty-four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $146.44.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 beat on top and bottom line: Gilead reported Q4 EPS of $1.86 vs. consensus ~$1.83 and revenue roughly $7.9B, powered by HIV and liver‑disease franchises — the core beat is the primary near‑term driver of the rally. Gilead quarterly results beat Wall Street estimates
• Positive Sentiment: Multiple analyst upgrades/price‑target raises: Banks including Morgan Stanley, JPMorgan, Wells Fargo, Needham and others bumped targets (some to $160–$177+), reinforcing buy/overweight sentiment and supporting the stock pop. Morgan Stanley raises price target
• Positive Sentiment: Yescarta label expansion and pipeline momentum: Positive commentary about CAR‑T (Yescarta) label expansion and new HIV options (Yeztugo) adds optionality to growth expectations. Yescarta label expansion and dividend growth
• Positive Sentiment: Dividend increase: Board raised the quarterly payout to $0.82 (3.8% increase), supporting income investors and reducing equity downside for dividend‑focused holders. Dividend announcement
• Neutral Sentiment: Investor commentary and transcripts: Earnings call and slides are available for detail on unit trends and margin commentary — useful for modeling but not an immediate directional driver. Earnings call transcript
• Neutral Sentiment: Short‑interest items in recent filings show no meaningful or reliable signal (reported zero/odd values), so ignore those as noise.
• Negative Sentiment: FY‑2026 guidance came in slightly light: Gilead set EPS guidance of $8.45–$8.85 and revenue guidance ~$29.6–$30.0B, marginally below consensus (~$30.1B / ~$8.69 EPS), which caused an initial after‑hours pullback and remains the main near‑term risk to sustaining the rally. Guidance story
• Negative Sentiment: Some cautious analyst views remain: A few firms (e.g., RBC with a lower PT) kept conservative ratings/targets, which could cap upside if other brokers re‑rate lower or fundamentals disappoint. Analyst notes (RBC)

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.